Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions

Ellens, H and Deng, S and Coleman, J and Bentz, J and Taub, ME and Ragueneau-Majlessi, I and Chung, SP and Heredi-Szabo, K and Neuhoff, S and Palm, J and Balimane, P and Zhang, L and Jamei, M and Hanna, I and O'Connor, M and Bednarczyk, D and Forsgard, M and Chu, X and Funk, C and Guo, A and Hillgren, KM and Li, L and Pak, AY and Perloff, ES and Rajaraman, G and Salphati, L and Taur, JS and Weitz, D and Wortelboer, HM and Xia, CQ and Xiao, G and Yamagata, T and Lee, CA (2013) Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions. DRUG METABOLISM AND DISPOSITION. pp. 1367-1374.

Item Type: Article
Additional Information: pubid: 24 nvp_institute: NIBR contributor_address: GlaxoSmithKline, Stat Sci, King Of Prussia, PA USA, GlaxoSmithKline, Drug Metab & Pharmacokinet, King Of Prussia, PA USA ; Pfizer Worldwide Res & Dev La Jolla Labs, Clin Res, San Diego, CA USA ; GlaxoSmithKline, Stat Sci, King Of Prussia, PA USA ; Drexel Univ, Dept Biol, Philadelphia, PA 19104 USA ; Boehringer Ingelheim Pharmaceut Inc, Drug Metab & Pharmacokinet, Ridgefield, CT USA ; Univ Washington, Dept Pharmaceut, Drug Interact Database Program, Seattle, WA 98195 USA ; SOLVO Biotechnol, Budapest, Hungary ; SimCyp, Sheffield, S Yorkshire, England ; AstraZeneca Res & Dev, CVGI iMed DMPK, Innovat Med, Molndal, Sweden ; Bristol Myers Squibb, Pharmaceut Candidate Optimizat, Princeton, NJ USA ; US FDA, Off Clin Pharmacol, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD USA ; Novartis Inst BioMed Res, Drug Metab & Pharmacokinet, E Hanover, NJ USA ; Optivia, Biotechnol, Menlo Pk, CA USA ; AstraZeneca Res & Dev, Global Drug Metab & Pharmacokinet, Molndal, Sweden ; Merck Co, Dept Pharmacokinet Pharmacodynam & Drug Metab, Rahway, NJ USA ; Hoffmann La Roche AG, Nonclin Drug Safety, Basel, Switzerland ; Lilly Res Labs, Investigat Drug Disposit, Indianapolis, IN USA ; Absorpt Syst LP, Exton, PA USA ; BD Gentest Contract Res Serv, BD Bioscie Discovery Labware, Woburn, MA USA ; CellzDirect Life Technol Ltd, Austin, TX USA ; Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA ; Eisai Inc, Andover, MA USA ; Sanofi Aventis, DSAR Drug Disposit FF, Res & Dev, Frankfurt, Germany ; TNO, NL-3700 AJ Zeist, Netherlands ; Millennium Pharmaceut Inc, Cambridge, MA USA ; Biogen Idec Inc, Drug Metab & Pharmacokinet, Cambridge, MA USA ; Merck Serono, Inst Drug Metab & Pharmacokinet, Grafing, Germany ; Pfizer Worldwide Res & Dev La Jolla Labs, Pharmacokinet Dynam & Metab, San Diego, CA USA ; GlaxoSmithKline, Stat Sci, King Of Prussia, PA USA; GlaxoSmithKline, Drug Metab & Pharmacokinet, King Of Prussia, PA USA; Ellens, H; GlaxoSmithKline, Drug Metab & Pharmacokinet, King Of Prussia, PA USA
Date Deposited: 13 Oct 2015 13:13
Last Modified: 13 Oct 2015 13:13
URI: https://oak.novartis.com/id/eprint/21876

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.